In clinical practice, EGFR-targeted therapy (cetuximab) can improve the overall survival (OS) in KRAS wild type colorectal cancer patients [6], which is an important method of targeted therapy for colorectal cancer patients. The gene discussed is EGFR; the disease is colorectal cancer.